IP Library › Granted Patent US 12,521,413
Granted Patent B2
US 12,521,413 · App. 18/038,738 · Granted Jan 13, 2026

Molecular basis of fatty liver inhibition by sodium borates

Inventors: Fikrettin Sahin (Istanbul, TR); Emre Cebeci (Istanbul, TR); Huseyin Abdik (Istanbul, TR)
Assignee: YEDITEPE UNIVERSITESI
A61K33/22A61P1/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,413
App. No.
18/038,738
Granted
Jan 13, 2026
Kind
B2
Abstract

Sodium borates are provided as the sole active ingredient to prevent and/or treat fatty liver. In addition, the sodium borates reduce the expression levels of ADIPOR2, PRKAG2, IRS1, PIK3R1, NFKB1, MAP3K11, BID, CYCS, BAX, CASP3 and TGFB1 genes in the non-alcoholic fatty liver pathway and thereby to prevent and/or treat fatty liver by inhibiting the functioning of the non-alcoholic fatty liver pathway.

Claims (5)

1 . A composition formulated for oral administration for use to treat and/or prevent non-alcoholic fatty liver disease (NAFLD) by downregulating disease-associated gene expression, consisting of phosphate-buffered saline (PBS) and at least one sodium borate selected from the group consisting of sodium tetraborate, sodium pentaborate, and sodium octaborate.

2 . The composition according to claim 1 , wherein the daily dose of the at least one sodium borate for an 80 kg human subject is from 0.66 g to 2 g, based on allometric scaling from efficacious doses demonstrated in murine in vivo models.

3 . The composition according to claim 1 , consisting of PBS and sodium tetraborate.

4 . The composition according to claim 1 , consisting of PBS and sodium pentaborate.

5 . The composition according to claim 1 , consisting of PBS and sodium octaborate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2023
From: SAHIN, FIKRETTIN; CEBECI, EMRE; ABDIK, HUSEYIN
To: YEDITEPE UNIVERSITESI
Reel/Frame 064006/0249 →
Continuity (1)
Related Publication 20240000831A1 · Jan 4, 2024
References Cited (20)
US 5587221A · McCamy · 1996 [cited by examiner]
US 9655990B2 · Sahin · 2017 [cited by examiner]
US 9962405B2 · Sahin · 2018 [cited by examiner]
US 10124082B2 · Santini · 2018 [cited by examiner]
US 11123432B2 · Sahin · 2021 [cited by examiner]
US 20240050468A1 · Sahin · 2024 [cited by examiner]
EP 2351748A1 · 2011 [cited by applicant]
EP 3134417A1 · 2017 [cited by applicant]
WO 2019126090A1 · 2019 [cited by applicant]
WO 2020006294A1 · 2020 [cited by applicant]
Woods; Environmental Health Perspectives; vol. 102, Issue: Suppl 7; pp. 5-11. Published Nov. 1, 1994. [cited by examiner]
Ayala Wollman, et al., Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice, Nutrients, 2019, pp. 1-18, vol. 11, 3044. [cited by applicant]
Monjur Ahmed, Non-alcoholic fatty liver disease in 2015, World Journal of Hepatology, 2015, pp. 1450-1459, vol. 7, Issue 11. [cited by applicant]
Brian J. Morris, Seven sirtuins for seven deadly diseases of aging, Free Radical Biology and Medicine, 2013, pp. 133-171, vol. 56. [cited by applicant]
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH), Clinical Trials Gov, 2012, pp. 1-8. [cited by applicant]
Manhal Olaywi, et al., Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review, Hepatobiliary Pancreat Dis Int, 2013, pp. 584-588, vol. 12, No. 6. [cited by applicant]
Aliye Sagkan Ozturk, Effects of Borax on the Pathogenic Mechanisms Leading to Fatty Liver, 2008, Doctorate Thesis Selcuk University, pp. 1-82. [cited by applicant]
Abdullah Basoglu, et al., Efficacy of Sodium Borate in the Prevention of Fatty Liver in Dairy Cows, J Vet Intern Med, 2002, pp. 732-735, vol. 16. [cited by applicant]
Ismail Kucukkurt, et al., The effects of dietary boron compounds in supplemented diet on hormonal activity and some biochemical parameters in rats, Toxicology and Industrial Health, 2015, pp. 255-260, vol. 31, No. 3. [cited by applicant]
Silvia Sookoian, et al., Repurposing drugs to target nonalcoholic steatohepatitis, World Journal of Gastroenterology, 2019, pp. 1783-1796, vol. 25, Issue 15. [cited by applicant]